Cited 7 times in
Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.